SPRI | Treatment Of Cystic Fibrosis And Other Rare Lung Diseases (2017 EN)

Discussion in 'Medicine' started by Kanka, Jul 22, 2017.

  1. Kanka

    Kanka Well-Known Member Loyal User

    Messages:
    16,037
    Likes Received:
    449
    Trophy Points:
    83
    [​IMG]

    Author: Arata Azuma (Editor), Michael S. Schechter (Editor)
    Full Title: Treatment Of Cystic Fibrosis And Other Rare Lung Diseases
    Publisher: Springer; 1st ed. 2017 edition (January 28, 2017)
    Year: 2017
    ISBN-13: 9783034809771 (978-3-0348-0977-1), 9783034809757 (978-3-0348-0975-7)
    ISBN-10: 3034809778, 3034809751
    Pages: 263
    Language: English
    Genre: Biomedical Sciences: Pharmacology & Toxicology
    File type: PDF (True)
    Quality: 10/10
    Price: 140.39 €


    This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions.

    It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.

    -------------
     
    Last edited by a moderator: Nov 28, 2019